Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
about
Philadelphia chromosome-like acute lymphoblastic leukemia.JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.Anti-CD19 resistance can "stem" from progenitors.High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.Clinical Impact of Genomic Information in Pediatric Leukemia.mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.How is the Ph-like signature being incorporated into ALL therapy?Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia.New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure.The genetic landscape of ganglioglioma.New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemiaKeeping PACE with Ph Positive to Ph-Like Detection in B-Lineage Acute Lymphoblastic Leukemia: A Practical and Cost Effective (PACE) Approach in a Resource Constrained Setting
P2860
Q43431904-742C2976-516F-4DDD-83FA-F7C7305A8504Q47095048-38F0D6FB-9486-4C9B-9FF7-5E3F8E53160FQ47103718-2CDF062C-002D-4107-AFBE-3E1BED21EC23Q47142310-B1698815-87C2-4D4E-AC1E-50DD19601F5BQ47221791-8D07D47E-385C-4C3C-A6C0-C78B387F93C3Q49787386-A310CCEB-B3DD-4637-8CAC-39B5CE27C66EQ50056301-EDE029BC-376B-4F9E-A6FE-7E4960CDC00CQ50098629-3078382B-B241-459E-B729-DE45DBE5C6BFQ50308754-BDBFDC30-4F10-4D10-BB8F-B5F40C65A3AFQ51839566-1E6BA5FF-0F4E-422B-A671-9AFBEADEA14EQ52575378-DD8E3213-9252-4B03-A41B-A845E847FFA6Q52593673-6E7050D8-DD13-4B6B-B166-5ECA279BD5C7Q54109030-F918F46D-2DB8-43DC-9BC5-25F2ACB4D044Q54976777-56A618A4-F3E3-46B6-BB63-6DD934FFBE76Q57821013-404FF41C-3F52-4892-881A-2E177C27D1C0Q58125084-BE0C793D-2746-46D2-8052-79046CB75CE7
P2860
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Targetable kinase gene fusions ...... the Children's Oncology Group.
@en
Targetable kinase gene fusions ...... the Children's Oncology Group.
@nl
type
label
Targetable kinase gene fusions ...... the Children's Oncology Group.
@en
Targetable kinase gene fusions ...... the Children's Oncology Group.
@nl
prefLabel
Targetable kinase gene fusions ...... the Children's Oncology Group.
@en
Targetable kinase gene fusions ...... the Children's Oncology Group.
@nl
P2093
P2860
P50
P1433
P1476
Targetable kinase gene fusions ...... the Children's Oncology Group.
@en
P2093
Andrew J Carroll
Anne L Angiolillo
Brent L Wood
Charles G Mullighan
Cheryl L Willman
Debbie Payne-Turner
Eileen Stonerock
Elizabeth A Raetz
Heather Jenkins
P2860
P304
P356
10.1182/BLOOD-2016-12-758979
P407
P577
2017-04-13T00:00:00Z